Production of antibodies and antibody fragments containing non-natural amino acids in Escherichia coli

References

• Suzuki M, Kato C, Kato A. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol. 2015;28(3):133–11. doi:10.1293/tox.2015-0031.
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491–95. doi:10.1038/d41573-021-00079-7.
   PubMed Web of Science ®Google Scholar
• Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020;9(3):34. doi:10.3390/antib9030034.
   PubMedGoogle Scholar
• Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, Chen S, Pan L. Emerging new therapeutic antibody derivatives for cancer treatment. Sig Transduct Target Ther. 2022;7:1–28. doi:10.1038/s41392-021-00868-x.
   PubMed Web of Science ®Google Scholar
• Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, JHSeki CA, Ou X, Fowler E, Ashman N, Takada Y, Takada Y. et al. Site-selective modification strategies in antibody–drug conjugates. Chem Soc Rev [Internet]. 2021;50(2):1305–53. doi:10.1039/D0CS00310G.
   PubMed Web of Science ®Google Scholar
• Kline T, Steiner AR, Penta K, Sato AK, Hallam TJ, Yin G. Methods to Make Homogenous Antibody Drug Conjugates. Pharm Res. 2015;32(11):3480–93. doi:10.1007/s11095-014-1596-8.
   PubMed Web of Science ®Google Scholar
• Akkapeddi P, Azizi S-A, Freedy AM, Cal PHMSD, Gois PMP, Bernardes GJL. Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry. Chem Sci. 2016;7(5):2954–63. doi:10.1039/C6SC00170J.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925–32. doi:10.1038/nbt.1480.
   PubMed Web of Science ®Google Scholar
• Lieser RM, Yur D, Sullivan MO, Chen W. Site-specific bioconjugation approaches for enhanced delivery of protein therapeutics and protein drug carriers. Bioconjugate Chem. 2020;31(10):2272–82. doi:10.1021/acs.bioconjchem.0c00456.
   PubMed Web of Science ®Google Scholar
• Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6(1):34–45. doi:10.4161/mabs.27022.
   PubMed Web of Science ®Google Scholar
• Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K. et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012;109(40):16101–06. doi:10.1073/pnas.1211023109.
   PubMed Web of Science ®Google Scholar
• Roy G, Reier J, Garcia A, Martin T, Rice M, Wang J, Prophet M, Christie R, Dall’acqua W, Ahuja S. et al. Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences. MAbs. 2019;12(1):1684749. doi:10.1080/19420862.2019.1684749.
   Web of Science ®Google Scholar
• Robinson M-P, Ke N, Lobstein J, Peterson C, Szkodny A, Mansell TJ, Tuckey C, Riggs PD, Colussi PA, Noren CJ. et al. Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria. Nat Commun. 2015;6(1):8072. doi:10.1038/ncomms9072.
   PubMedGoogle Scholar
• Huleani S, Roberts MR, Beales L, Papaioannou EH. Escherichia coli as an antibody expression host for the production of diagnostic proteins: significance and expression. Crit Rev Biotechnol. 2022;42(5):756–73. doi:10.1080/07388551.2021.1967871.
   PubMed Web of Science ®Google Scholar
• Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P. et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods. 2002;263(1–2):133–47. doi:10.1016/S0022-1759(02)00036-4.
   PubMed Web of Science ®Google Scholar
• Eaglesham JB, Garcia A, Berkmen M. Production of antibodies in SHuffle Escherichia coli strains [internet. In: Methods in enzymology. Elsevier;2021. pp. 105–44. cited 2023 Jan 6. https://linkinghub.elsevier.com/retrieve/pii/S0076687921002998.
   Google Scholar
• Production of antibodies and antibody fragments in Escherichia coli | SpringerLink [Internet]. [Accessed 2023 Mar 7]. https://link.springer.com/protocol/10.1007/978-3-642-01147-4_26.
   Google Scholar
• Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, Tran C, Uter NT, Yin G, Rivers PJ. et al. Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjugate Chem. 2014;25(2):351–61. doi:10.1021/bc400490z.
   PubMed Web of Science ®Google Scholar
• Groff D, Carlos NA, Chen R, Hanson JA, Liang S, Armstrong S, Li X, Zhou S, Steiner A, Hallam TJ. et al. Development of an E. coli strain for cell‐free ADC manufacturing. Biotechnol Bioeng. 2022;119(1):162–75. doi:10.1002/bit.27961.
   PubMed Web of Science ®Google Scholar
• Young TS, Ahmad I, Brock A, Schultz PG. Expanding the genetic repertoire of the methylotrophic yeast pichia pastoris. Biochemistry. 2009;48(12):2643–53. doi:10.1021/bi802178k.
   PubMed Web of Science ®Google Scholar
• de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact. 2009;8(1):26. doi:10.1186/1475-2859-8-26.
   PubMedGoogle Scholar
• Arakawa T, Ejima D. Refolding technologies for antibody fragments. Antibodies. 2014;3(2):232–41. doi:10.3390/antib3020232.
   Google Scholar
• Misawa S, Kumagai I. Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies. Biopolymers. 1999;51(4):297–307. doi:10.1002/(SICI)1097-0282(1999)51:4<297:AID-BIP5>3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• Sarker A, Rathore AS, Gupta RD. Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process. Microb Cell Fact. 2019;18(1):5. doi:10.1186/s12934-019-1053-9.
   PubMedGoogle Scholar
• Reilly D, Yansura DG. Production of Antibodies and Antibody Fragments in Escherichia coli | SpringerLink. Internet. [Accessed 2023 Mar 7]. https://link.springer.com/protocol/10.1007/978-3-642-01147-4_26
   Google Scholar
• Hanson J, Groff D, Carlos A, Usman H, Fong K, Yu A, Armstrong S, Dwyer A, Masikat MR, Yuan D. et al. An integrated in vivo/in vitro protein production platform for site-specific antibody drug conjugates. Bioengineering. 2023;10(3):304. doi:10.3390/bioengineering10030304.
   PubMedGoogle Scholar
• Wang L, Brock A, Herberich B, Schultz PG. Expanding the genetic code of Escherichia coli. Science. 2001;292(5516):498–500. doi:10.1126/science.1060077.
   PubMed Web of Science ®Google Scholar
• Groff D, Wang F, Jockusch S, Turro NJ, Schultz PG. A new strategy to photoactivate green fluorescent protein. Angew Chem Int Ed. 2010;49(42):7677–79. doi:10.1002/anie.201003797.
   PubMed Web of Science ®Google Scholar
• Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. scFv antibody: principles and clinical application. J Immunol Res. 2012;2012:e980250. doi:10.1155/2012/980250.
   Google Scholar
• Nelson AL. Antibody fragments. MAbs. 2010;2(1):77–83. doi:10.4161/mabs.2.1.10786.
   PubMed Web of Science ®Google Scholar
• Wang R, Xiang S, Feng Y, Srinivas S, Zhang Y, Lin M, Wang S. Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone skp. Front Cell Infect Microbiol [Internet]. 2013; 3. 10.3389/fcimb.2013.00072
   Web of Science ®Google Scholar
• Zhang J, Zhao Y, Cao Y, Yu Z, Wang G, Li Y, Ye X, Li C, Lin X, Song H. sRNA-based screening chromosomal gene targets and modular designing Escherichia coli for high-titer production of aglycosylated Immunoglobulin G. ACS Synth Biol. 2020;9(6):1385–94. doi:10.1021/acssynbio.0c00062.
   PubMed Web of Science ®Google Scholar
• Guo J, Melançon CE, Lee HS, Groff D, Schultz PG. Evolution of amber suppressor tRNAs for efficient bacterial production of proteins containing nonnatural amino acids. Angew Chem Int Ed Engl. 2009;48(48):9148–51. doi:10.1002/anie.200904035.
   PubMed Web of Science ®Google Scholar
• Cellitti SE, Jones DH, Lagpacan L, Hao X, Zhang Q, Hu H, Brittain SM, Brinker A, Caldwell J, Bursulaya B. et al. In vivo incorporation of unnatural amino acids to probe structure, dynamics, and ligand binding in a large protein by nuclear magnetic resonance spectroscopy. J Am Chem Soc. 2008;130(29):9268–81. doi:10.1021/ja801602q.
   PubMed Web of Science ®Google Scholar
• Tan Z, Ehamparanathan V, Ren T, Tang P, Hoffman L, Kuang J, Liu P, Huang C, Du C, Tao L. et al. On-column disulfide bond formation of monoclonal antibodies during protein a chromatography eliminates low molecular weight species and rescues reduced antibodies. MAbs. 2020;12(1):1829333. doi:10.1080/19420862.2020.1829333.
   PubMed Web of Science ®Google Scholar
• Abrahams CL, Li X, Embry M, Yu A, Krimm S, Krueger S, Greenland NY, Wen KW, Jones C, DeAlmeida V. et al. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Oncotarget. 2018;9(102):37700–14. doi:10.18632/oncotarget.26491.
   PubMedGoogle Scholar
• Lobstein J, Emrich CA, Jeans C, Faulkner M, Riggs P, Berkmen M. Shuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. Microb Cell Fact. 2012;11(1):753. doi:10.1186/1475-2859-11-56.
   Google Scholar
• Groff D. E. coli strains having an oxidative cytoplasm [Internet]. 2023 [Accessed 2023 Aug 22]. https://patents.google.com/patent/US20230002722A1/en?inventor=daniel+groff&oq=daniel+groff
   Google Scholar
• Rashid MH. Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation. MAbs. 2022;14(1):2111748. doi:10.1080/19420862.2022.2111748.
   PubMed Web of Science ®Google Scholar
• Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100(8):3451–61. doi:10.1007/s00253-016-7388-9.
   PubMed Web of Science ®Google Scholar
• Riley NM, Hebert AS, Westphall MS, Coon JJ. Capturing site-specific heterogeneity with large-scale N-glycoproteome analysis. Nat Commun. 2019;10(1):1311. doi:10.1038/s41467-019-09222-w.
   PubMedGoogle Scholar
• Wu TT, Kabat EA. An analysis of the sequences of the variable regions of bence jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med. 1970;132(2):211–50. doi:10.1084/jem.132.2.211.
   PubMed Web of Science ®Google Scholar
• Groff D, Armstrong S, Rivers PJ, Zhang J, Yang J, Green E, Rozzelle J, Liang S, Kittle JD, Steiner AR. et al. Engineering toward a bacterial “endoplasmic reticulum” for the rapid expression of immunoglobulin proteins. MAbs. 2014;6(3):671–78. doi:10.4161/mabs.28172.
   PubMed Web of Science ®Google Scholar